NEW YORK, Oct. 19 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Triple Analysis: Apoptosis, Angiogenesis and Protein Kinase Inhibitors
This triple analysis focuses on cancer drug development strategies by mechanism/target/effect of Apoptosis, Angiogenesis and Protein Kinase Inhibitors. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.
Below is a short synopsis of each part included in this report:
Part I: Apoptosis
The apoptosis report part comprises defined and up to date development strategies for 171 apoptotic drugs in oncology (519 projects) within the portfolio of 125 investigators, from Ceased to Pre-registration. This report part extensively analyses 146 identified targets of apoptotic drugs, organized into 120 drug target strategies, and assesses them in 53 different cancer indications.
This part is based on the following publication:
Apoptotic Therapeutics in Oncology - Where to Commercialize?
Part II: Angiogenesis
The angiogenesis report part comprises defined and up to date development strategies for 239 drugs affecting angiogenesis in oncology within the portfolio of 148 investigators, from Preclinical to Marketed. This report part extensively analyses 174 identified targets of angiogenesis affecting drugs, organized into 167 drug target strategies, and assesses them in 64 different cancer indications.
This part is based on the following publication:
Commercializing Cancer Drugs Affecting Angiogenesis: A Decision Support Tool for Optimizing the Pipeline
Part III: Protein Kinase Inhibitors
The protein kinase report comprises defined and up to date development strategies for 409 protein kinase drugs (990 projects) within the portfolio of 160 investigators, from Ceased to Marketed. This report part extensively analyses 133 identified targets of protein kinase drugs, organized into 200 drug target strategies, and assesses them in 57 different cancer indications.
This part is based on the following publication:
Protein Kinase Therapeutics in Oncology - Where to Commercialize?
The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies' pipeline and portfolio planning (PPP) in cancer by:
* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives
* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties
* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities
* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities
* Supporting development of integrative molecule, pathway and disease area strategies
* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment
This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.
Key Topics Covered:
Part I: Apoptosis
5.1 The Scope of this Report 27
6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment (146 Drug Targets) 32-276
7 The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug Target Profiles Identified in the Cancer Apoptotic Therapeutic Pipeline? (120 Drug Target Strategies and 171 Drugs) 277-311
8 Compound Strategies at Work: Competitive Benchmarking of Apoptotic Drugs in Oncology by Compound Type (7 Different Compound Strategies) 312-355
9 Selecting Cancer Indications for Apoptotic Therapeutics (53 Cancer Indications) 356-440
10 Portfolio Planning: Competitive Benchmarking of Apoptotic Cancer Therapeutic Pipeline by Investigator (125 Investigators) 441-793
12 Drug Index 794
13 Company Index 799
Figures: Includes 6 Figures
Tables: Includes 248 Tables
Total Number of Pages: 803
Part II: Angiogenesis
5.1 The Scope of this Report 35
6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment (174 Drug Targets) 39-366
7 Emerging New Products to Established Ones: Drug Target Strategies of Cancer Drugs Affecting Angiogenesis by their Highest Stage of Development (167 Drug Target Strategies and 239 Drugs) 367-437
8 Compound Strategies at Work: Competitive Benchmarking of Cancer Drugs Affecting Angiogenesis by Compound Strategy (7 Different Compound Strategies) 438-485
9 Selecting Cancer Indications for Angiogenesis Affecting Drugs in Oncology (64 Cancer Indications) 486-643
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Angiogenesis Affecting Drug Pipeline in Oncology by Investigator (148 Investigators) 644-1211
10 Disclaimer 1212
11 Drug Index 1213
12 Company Index 1221
Figures: Includes 7 Figures
Tables: Includes 300 Tables
Total Number of Pages: 1227
Part III: Protein Kinase Inhibitors
5.1 The Scope of this Report 30
6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment (133 Drug Targets) 36-336
7 The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug Target Profiles Identified in the Cancer Protein Kinase Therapeutic Pipeline? (200 Drug Target Strategies and 409 Drugs) 337-407
8 Compound Strategies at Work: Competitive Benchmarking of Protein Kinase Drugs in Oncology by Compound Type (7 Compound Strategies) 408-495
9 Selecting Cancer Indications for Protein Kinase Therapeutics (57 Different Cancer Indications) 496-649
10 Portfolio Planning: Competitive Benchmarking of Protein Kinase Cancer Therapeutic Pipeline by Investigator (160 Investigators) 650-1417
12 Drug Index 1419
13 Company Index 1433
Figures: Includes 6 Figures
Tables: Includes 302 Tables
Total Number of Pages: 1442
To order this report:
Drug Discovery and Development Industry: Triple Analysis: Apoptosis, Angiogenesis and Protein Kinase Inhibitors
Drug Discovery and Development Business News
Check our Company Profile, SWOT and Revenue Analysis!
SOURCE Reportlinker